Diagnostic value of tripartite magnetic resonance imaging model based on T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced imaging for prostatitis, prostatic hyperplasia and prostate cancer

To assess the value of tripartite magnetic resonance imaging model based on T2-weighted imaging (T2-WI), diffusion-weighted imaging (DWI) as well as dynamic contrast-enhanced imaging (DCE) for the diagnosis of prostatitis, prostatic hyperplasia and prostate cancer.

A total of 100 patients with prostatic diseases were selected from our hospital from January 2020 to December 2022. All patients underwent T2-WI, DWI and DCE examination.

Among the 100 suspected patients, 40 were diagnosed with prostate cancer, 30 were prostatitis, and 30 were prostate hyperplasia. Apparent diffusion coefficient (ADC) value was reduced in prostate cancer patients compared to the prostatic hyperplasia as well as prostatitis groups (P<0.05). No difference was discovered in ADC value between the prostatic prostatic hyperplasia and prostatitis groups (P>0.05). Moreover, the diagnosis efficacy of the tripartite magnetic resonance imaging model was higher compared to those of prostate imaging reporting and data system version 2 (PI-RADS V2).

The tripartite magnetic resonance imaging model based on T2-WI, DWI, as well as DCE has high diagnostic accuracy in prostatic diseases, with high sensitivity and low misdiagnosis rate, which might be valuable in clinical application.